script.reportAU
Oncology

Atezolizumab

Brand: Tecentriq®SC

PBAC's latest decision on Atezolizumab: Recommended with restriction (2024). Considered for Subcutaneous injection formulation for multiple cancer indications including locally advanced or metastatic NSCLC, stage IV metastatic NSCLC, extensive-stage small cell lung cancer, hepatocellular carcinoma, and resected early-stage NSCLC.

PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
11
first 2017
PBS spend
$274M
38,018 scripts · 2024

Eligible population

Patients with locally advanced or metastatic NSCLC, stage IV metastatic NSCLC, extensive-stage small cell lung cancer, advanced hepatocellular carcinoma, and resected early-stage NSCLC requiring atezolizumab treatment.

Therapy area
Oncology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Surrogate
Key trials
IMscin001
Comparator
atezolizumab IV
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis conducted; no ICER calculated as the submission demonstrated cost-neutrality between atezolizumab SC and IV formulations.
ICER (historical)
$45k/QALY–$75k/QALY in an earlier submission (2019) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.

PBS expenditure

The Australian government paid $274M in PBS benefits for Atezolizumab in 2024 across 38,018 scripts, at $7,213 per script.

Submission history

Similar precedents

Open on full dashboard →